Lead integrity management in Sprint Fidelis and Riata leads

Implantable cardiac devices extend lives, but safe therapy depends on the integrity of their leads. The histories of the Sprint Fidelis and Riata families showed that an apparently minor mechanical weakness can produce ventricular oversensing, inappropriate shocks, loss of capture or failure to deliver lifesaving therapy. Their experience remains relevant to contemporary device follow-up, post-market surveillance and informed consent. Learn more about Idiopathic Premature Ventricular Contractions Indications For Ablation In Asymptomatic Patients.

Effective management now combines accurate implant records, scheduled and remote device monitoring, symptom assessment, and prompt access to specialist review. No single impedance value or remote alert can exclude a lead problem. Instead, clinicians should interpret trends, stored electrograms, clinical events and the specific construction of the implanted lead as parts of one surveillance system. Learn more about Ablation Of Outflow Tract Ventricular Arrhythmias Anatomic Challenges.

Why the recalls changed device follow-up

Global safety actions involving Sprint Fidelis leads began around 2008, while Medtronic’s Riata and Riata ST leads were withdrawn in 2012. Several Sprint Fidelis atrial models and related variants had experienced conductor fractures involving the fixation or connector region. Riata leads were affected by damage associated with insertion instruments, including components used during lead preparation or ablation-catheter placement.

These were not simply reports of increased pacing thresholds. Intermittent conductor fracture could generate electrical noise that the device interpreted as ventricular tachycardia. In patients with an implantable cardioverter-defibrillator, that noise could trigger inappropriate shocks. Other presentations included failure to pace, abnormal sensing, and therapy inhibition when noise-protection algorithms classified genuine arrhythmia incorrectly.

The recalls exposed weaknesses in how manufacturers, implanting centres and regulators shared model-specific information. In Australia, the Therapeutic Goods Administration oversees the Australian Register of Therapeutic Goods and can oversee recalls and safety actions involving sponsored devices. Historical model identifiers should therefore be checked against TGA safety alerts, recalls and Australian Public Assessment Reports, as well as international notices. Clinical teams should retain implant dates, lead models, serial or lot details and documentation of any previous lead revision.

How lead damage causes arrhythmia

Lead failure usually begins with a mechanical defect and then becomes an electrical problem. Repeated movement at an active-fixation point, strain near the connector or damage during implantation can fracture the internal conductor. The outer insulation may remain intact around part of the defect, allowing the device to measure a normal impedance between formal checks. Intermittent contact can nevertheless produce brief noise bursts that coincide with movement or a particular arm position.

The Riata experience highlighted the importance of handling technique. Inserting a guidewire or preparing the lead for ablation could damage the conductor or insulation in ways that were difficult to appreciate during implantation. Routine measurement immediately after surgery might appear satisfactory, masking a progressive or position-dependent defect. Training, sterile technique, appropriate instrument use and careful assessment of lead mobility are therefore integral components of lead integrity management.

Different defects generate different signals. Insulation failure may produce low impedance or current drain, while a fractured conductor may cause a sudden impedance rise, intermittent high impedance or unstable sensing. The clinical consequence can be inappropriate therapy, loss of capture, oversensing or failure to defibrillate. Device alerts are useful, but they depend on the sensing configuration, noise filters and algorithm used by that manufacturer and programming generation.

Identifying patients at risk

A defensible implant record is the foundation of surveillance. For every patient with a legacy device, reconcile the device card, implanting-centre records, manufacturer details, lead model, implantation date and any prior generator or lead replacement. Record whether a lead was capped, abandoned or extracted. A new generator does not correct an old lead, so generator age should never be used as a surrogate for lead integrity.

Clinical review should ask specifically about shocks, device beeping, palpitations, light-headedness, syncope, fatigue and arm or chest discomfort around the implant. Patients often notice a temporal relationship with exercise, gardening, reaching or sleeping position. For older patients, relatives and carers may provide more reliable information about nocturnal events or an unusual sequence of palpitations and dizziness.

When telemetry is equivocal, clinicians must distinguish intrinsic ventricular ectopy from lead-generated noise. The Journal of Arrhythmia’s discussion of [idiopathic ventricular ectopy] provides useful context for assessing genuine ventricular activity after device artefact has been excluded. Ambulatory ECG monitoring, symptom diaries and, when appropriate, correlation between patient symptoms and stored or transmitted electrograms can support this distinction.

Australian geography adds another layer. Implanting and extraction services are concentrated around Sydney, Melbourne, Brisbane and other major centres, while patients in rural New South Wales, Queensland, Western Australia, South Australia and the Northern Territory may travel considerable distances for review. Telehealth and remote interrogation reduce some burdens, but selected patients still require aeromedical transport through services such as the Royal Flying Doctor Service or travel to a metropolitan device clinic.

Interrogation and remote monitoring strategy

In-person interrogation remains important for high-risk leads and after symptoms or alerts. Evaluation should include battery status, programmed parameters, pacing thresholds, sensing amplitudes, lead impedance history and the integrity of device algorithms. Stored intracardiac electrograms can show pacing artefacts, noise, ventricular oversensing and the relationship between device classification and delivered therapy. A current impedance within the reference range does not exclude an intermittent fracture.

Remote monitoring should provide scheduled transmissions and clinically prioritised alerts, with protocols for who reviews each result and how quickly. Continuous connectivity can reveal intermittent events, but scheduled transmissions remain valuable where continuous monitoring is unavailable. Many modern systems also provide lead-status measurements, noise counters and high-impedance or lead-impedance alerts. These features should complement interrogation rather than create an expectation that the platform will detect every failure.

Connectivity and workload are practical Australian considerations. NBN availability, mobile coverage and reliable electricity vary across metropolitan, regional and remote areas. A transmission failure may reflect the local network rather than the patient or device. Clinics should maintain alternatives for patients without home internet, use appropriately timed mobile or landline processes, and avoid unnecessary alert fatigue by combining automated thresholds with clinical review and scheduled assessments.

Remote surveillance must also be structured around the patient’s risk. A patient with prior inappropriate therapy, repeated noise alerts, syncope or a documented model associated with a recall warrants early assessment. Stable patients without concerning symptoms may remain on scheduled surveillance, but the interval should reflect the lead’s history rather than an arbitrary assumption that all implants are equivalent.

Deciding when intervention is needed

Repeated inappropriate shocks, syncope, loss of capture, inability to sense or suspected failure to defibrillate require urgent device-clinic evaluation. Clinicians should obtain the stored electrograms, determine whether the event represents lead noise or a genuine arrhythmia, and assess whether therapy was delivered appropriately. Reprogramming may reduce inappropriate shocks or noise classification in selected patients, but it cannot repair a mechanically defective lead.

The decision to replace, abandon or extract a lead must be individualised. Generator replacement alone will not restore a failed lead. Leaving a damaged lead in place may be reasonable when the risk is low and extraction would be hazardous, but it requires a defined monitoring plan. Lead extraction may become necessary when the lead cannot safely be abandoned, causes infection or erosion, or compromises the ability to deliver appropriate therapy. Cardiac injury and procedural complications must be weighed against the probability of further device malfunction.

True ventricular arrhythmias require a separate treatment pathway. Localising the focus remains critical, and the Journal of Arrhythmia’s account of [outflow tract anatomy] illustrates how anatomical understanding can influence ablation decisions. Ablation does not correct lead noise, however, and apparent ventricular tachycardia on a device tracing should not be treated until artefact and genuine arrhythmia have been distinguished.

Patients should receive a written plan for shocks, palpitations, syncope and device alerts. Unexplained therapy or loss of consciousness warrants prompt contact with the treating centre and emergency assessment when clinically indicated. In Australia, emergency access is through 000, while non-urgent concerns should go to the implanting or follow-up service. Driving advice must be individualised, particularly for commercial drivers and anyone whose event could involve loss of consciousness.

Lessons for contemporary practice

The historical failures influenced lead design, including conductor strength, insulation integrity, connector strain relief and fixation mechanics. They also changed surgical technique, manufacturing surveillance and post-approval follow-up. Contemporary surveillance should treat a complaint, fracture pattern or device revision as evidence relevant to other patients with the same model, rather than as an isolated case.

Australian services need systems that connect national regulatory information with local clinical data. Public and private device clinics should reconcile recall lists, document unsuccessful patient contacts and arrange surveillance when risk persists. Multidisciplinary teams should include cardiac electrophysiologists, device nurses and technicians, with clear escalation pathways to lead-extraction specialists. For trainees, case-based teaching should include Sprint Fidelis and Riata mechanisms, noise interpretation, stored electrograms and the consequences of inappropriate shock.

Funding and data handling shape how surveillance can be delivered. Medicare Services Listed items support specified device interrogation and related services, but public outpatient access, private billing and patient travel costs vary. Clinics using vendor-hosted remote platforms should also consider the Australian Privacy Principles when handling transmitted health information and engaging service providers. Everyday Australian activities—beach swimming, gardening, cycling and contact sport—should inform practical advice without implying that ordinary movement causes failure in properly functioning leads.

Audit lead records, verify monitoring and act on suspected failure

Start with a structured audit of patients carrying legacy Sprint Fidelis or Riata models, including lead identifiers, symptoms, previous alerts and remote-transmission status. Confirm that every high-risk patient has an accessible pathway to interrogation, electrogram review and specialist intervention.

Review remote-monitoring workflows for missed transmissions, unclosed alerts and inadequate escalation, then contact patients whose records remain uncertain. Patients should carry current device identification, record shocks or symptoms promptly and avoid assuming that a new generator has resolved an old lead problem.

Act today: reconcile the lead inventory, verify remote surveillance and arrange expedited review for suspected integrity failure.